Glucometacin enteric-coated tablets

This product is a compound preparation with anti-inflammatory, antipyretic, analgesic and anti-rheumatic effects. After oral administration, "glucosamine hydrochloride" is mixed into bone tissue earlier, promoting the synthesis of polysaccharide compounds, increasing the viscosity of synovial fluid of bone joints, improving and repairing the metabolism of joint cartilage, and can also play the role of "indomethacin" in inhibiting the synthesis of prostaglandins, stopping the formation of pain nerve impulses in inflammatory tissues, and inhibiting inflammatory reactions, including inhibiting the chemotaxis of white blood cells and the release of lysosomal enzymes. The compound preparation composed of the two drugs combines the advantages of the two drugs, overcomes their respective shortcomings, and pharmacodynamics shows that it plays an additive role.

This product is a compound preparation, its components are: each tablet contains 25 mg of indomethacin and 75 mg of glucosamine hydrochloride.

This product is an enteric-coated tablet. After removing the coating, it appears off-white or light yellow.

This product is a non-steroidal anti-inflammatory drug, used for symptomatic treatment of anti-inflammatory, antipyretic and analgesic, and should be used in combination with drugs to control the progression of the disease. It is suitable for the treatment of knee and lumbar hyperplastic arthritis, acute and chronic rheumatism, rheumatoid arthritis, osteoarthritis, scapulohumeral periarthritis, ankylosing spondylitis, Reiter's syndrome, neuralgia, migraine, dysmenorrhea, biliary colic, and fever and headache caused by colds.

Oral administration: 1-2 tablets at a time, 1-2 times a day, or as directed by your doctor.

The main ingredient of this product, indomethacin, can cause the following adverse reactions: 1. Digestive tract discomfort, such as stomach pain, acid reflux, etc., and in some cases, gastric bleeding, perforation, ulcers, etc.; 2. Nervous system: headache, dizziness, anxiety, insomnia, etc.; 3. Kidney: hematuria, etc., especially for the elderly; 4. Skin: rash, erythema; 5. Suppression of hematopoietic function; 6. Allergic reactions: asthma, angioedema, shock.

It is contraindicated if you are allergic to this product, aspirin, or other non-steroidal anti-inflammatory drugs, or have angioedema or bronchospasm.

Precautions for children: This experiment has not been conducted and there are no reliable references. Precautions for pregnancy and lactation: 1. This product can cause fetal ductus arteriosus occlusion and persistent pulmonary hypertension when used in the last 3 months of pregnancy. It is contraindicated for pregnant women. 2. This product can be excreted from breast milk and can cause toxic and side effects in infants. It is contraindicated for lactating women. Precautions for the elderly: Elderly patients are prone to toxic reactions and should be used with caution.

The main drug of this product, indomethacin, has the following effects: 1. Long-term use with acetaminophen can increase kidney toxicity and side effects. When used with other non-steroidal anti-inflammatory drugs, the incidence of gastrointestinal ulcers increases. 2. When used with aspirin or other salicylates, it does not enhance the efficacy, but the gastrointestinal side effects increase significantly; due to the enhanced inhibition of platelet aggregation, it can increase the tendency of bleeding. 3. Drinking alcohol or using it with corticosteroids and adrenocorticotropic hormone can increase the risk of gastrointestinal ulcers or bleeding. 4. When used with digitalis drugs, this product can increase the blood concentration of digitalis (due to inhibition of renal clearance) and increase toxicity, so the dose of digitalis needs to be adjusted. 5. When used with heparin, oral anticoagulants and thrombolytics, because this product competes with them to bind to proteins, the anticoagulant effect is enhanced, and this product has the effect of inhibiting platelet aggregation. Therefore, there is a potential risk of increased bleeding. 6. This product can enhance the hypoglycemic effect when used in combination with insulin and oral hypoglycemic drugs, and the dose of hypoglycemic drugs needs to be adjusted. 7. When used with furosemide, it can weaken the latter's excretion and antihypertensive effects. The reason may be due to the inhibition of the synthesis of prostaglandins in the kidney. This product also has the effect of preventing furosemide, bumetanide and indapamide from enhancing plasma renin activity (PRA). This point should be noted when evaluating the significance of PRA in hypertensive patients. 8. When used in combination with triamterene, it can cause renal dysfunction (decreased creatinine clearance, azotemia). 9. When used in combination with nifedipine or verapamil, this product can increase the blood concentration of the latter two, thereby increasing toxicity. 10. Probenecid can reduce the clearance of this product from the kidney and bile, increase blood concentration, and increase toxicity. When used in combination, the dosage must be reduced. 11. When used in combination with colchicine and sulfinpyrazone, it can increase the risk of gastrointestinal ulcers and bleeding. 12. When used in combination with lithium salts, it can reduce the excretion of lithium from urine, increase blood concentration, and increase toxicity. 13. This product can increase the blood concentration of methotrexate and prolong the high blood concentration time. If patients who are taking this product need to be treated with medium or large doses of methotrexate, they should stop taking this product 24-28 hours in advance to avoid increasing toxicity. 14. When used together with the antiviral drug zidovudine, the latter's clearance rate can be reduced and its toxicity increased. At the same time, the toxicity of this product is also increased, so it should be avoided in combination.

Keep sealed.

Each tablet contains 25 mg of indomethacin and 75 mg of glucosamine hydrochloride

24 months.

Zhejiang Qianyuan Haili Sheng Pharmaceutical Co., Ltd.

• Founded in:

  1990-06-04

• Address:

  No. 66, Xingang 11th Road, Xingang Park, Zhoushan Economic Development Zone, Zhejiang Province

• Tax NO.:

  91330900148699778M

• Registered Funds:

  20 million yuan

• Website:

  Log in to view

• Email:

  Log in to view